Disease Markers

Review Article

Association between MnSOD Val16Ala Polymorphism and Cancer Risk: Evidence from 33,098 Cases and 37,831 Controls

Table 2

Meta-analysis of the association between MnSOD Val16Ala polymorphism and cancer risk.

Variables

Number of studies

Sample size (case/controls)

Homozygous

Heterozygous

Recessive

Dominant

Allele comparison

Ala/Ala versus Val/Val

Val/Ala versus Val/Val

Ala/Ala versus (Val/Val + Val/Ala)

(Ala/Ala + Val/Ala) versus Val/Val

Ala versus Val

OR (95% CI)

P ^het

OR (95% CI)

P ^het

OR (95% CI)

P ^het

OR (95% CI)

P ^het

OR (95% CI)

P ^het

All

33,098/37,831

1.09 (1.00–1.19)

<0.001

1.07 (1.02–1.12)

0.001

1.05 (0.99–1.11)

<0.001

1.08 (1.02–1.14)

<0.001

1.06 (1.02–1.11)

<0.001

Cancer type

Breast

12,479/12,603

1.03 (0.95–1.13)

0.276

1.02 (0.96–1.09)

0.302

1.02 (0.94–1.10)

0.157

1.01 (0.94–1.09)

0.066

1.02 (0.97–1.06)

0.226

Prostate

7101/9146

1.04 (0.87–1.24)

0.002

1.14 (1.05–1.24)

0.765

1.03 (0.94–1.14)

0.225

1.14 (1.05–1.23)

0.552

1.07 (1.00–1.15)

0.106

Lung

2021/2347

1.13 (0.63–2.04)

0.019

1.05 (0.76–1.46)

0.016

0.91 (0.72–1.14)

0.313

1.02 (0.78–1.32)

0.021

0.98 (0.80–1.21)

0.039

Bladder

1271/1270

0.66 (0.39–1.13)

0.002

0.91 (0.68–1.23)

0.049

1.01 (0.83–1.24)

0.520

0.93 (0.68–1.26)

0.021

0.97 (0.80–1.19)

0.033

Pancreatic

1422/2043

1.01 (0.59–1.73)

0.007

1.07 (0.77–1.49)

0.032

1.08 (0.77–1.50)

0.020

1.04 (0.70–1.55)

0.002

1.04 (0.76–1.43)

<0.001

CRC

2258/2180

1.02 (0.86–1.20)

0.856

1.04 (0.90–1.20)

0.733

0.99 (0.86–1.13)

0.967

1.03 (0.90–1.18)

0.733

1.01 (0.93–1.09)

0.863

Ovarian

716,1358

1.10 (0.85–1.42)

0.839

1.15 (0.92–1.45)

0.773

1.00 (0.81–1.23)

0.973

1.13 (0.92–1.40)

0.748

1.05 (0.92–1.19)

0.836

HCC

593/759

1.92 (0.85–4.36)

0.050

1.15 (0.66–2.00)

0.055

1.70 (0.97–2.97)

0.162

1.36 (0.67–2.76)

0.005

1.34 (0.76–2.35)

0.001

NHL

2123/2479

1.96 (0.96–4.00)

<0.001

1.03 (0.89–1.19)

0.551

1.08 (0.94–1.24)

0.357

1.05 (0.92–1.20)

0.831

1.05 (0.96–1.14)

0.849

Other cancers

3114/3646

1.79 (1.18–2.70)

<0.001

1.25 (1.05–1.49)

0.058

1.54 (1.07–2.20)

<0.001

1.32 (1.08–1.61)

0.001

1.32 (1.08–1.61)

<0.001

Ethnicity

Asian

5092/5748

1.82 (1.15–2.88)

0.020

1.10 (0.94–1.30)

0.001

1.76 (1.16–2.68)

0.065

1.08 (0.91–1.29)

<0.001

1.16 (0.96–1.40)

<0.001

Caucasian

23,738/26,121

1.03 (0.94–1.12)

<0.001

1.08 (1.03–1.13)

0.208

1.02 (0.96–1.08)

0.005

1.08 (1.02–1.14)

0.011

1.04 (1.00–1.09)

<0.001

African

1530/1758

1.58 (0.85–2.93)

<0.001

0.95 (0.80–1.12)

0.442

0.98 (0.79–1.21)

0.314

0.99 (0.81–1.20)

0.289

1.01 (0.87–1.17)

0.168

Mixed

2738/4204

1.11 (0.88–1.42)

0.141

0.98 (0.81–1.19)

0.196

1.12 (0.97–1.31)

0.187

1.02 (0.85–1.23)

0.177

1.06 (0.94–1.21)

0.107

Source of control

23,004/27,193

1.10 (1.01–1.19)

<0.001

1.07 (1.02–1.12)

0.263

1.02 (0.97–1.08)

0.071

1.07 (1.02–1.13)

0.071

1.04 (1.00–1.08)

0.006

10,094/10,638

1.09 (0.88–1.35)

<0.001

1.08 (0.98–1.20)

0.003

1.16 (1.01–1.34)

<0.001

1.10 (0.98–1.23)

<0.001

1.13 (1.03–1.24)

<0.001

Quality score

Low

7625/7608

1.15 (0.90–1.46)

<0.001

1.09 (0.98–1.22)

0.025

1.13 (0.99–1.29)

0.015

1.11 (0.98–1.26)

<0.001

1.12 (1.02–1.23)

<0.001

High

25,473/30,223

1.08 (1.00–1.17)

0.001

1.07 (1.02–1.13)

0.067

1.03 (0.97–1.09)

0.002

1.07 (1.02–1.14)

0.002

1.04 (1.00–1.09)

<0.001

Het: heterogeneity; CRC: colorectal cancer; HCC: hepatocellular carcinoma; NHL: non-Hodgkin’s lymphoma; PB: population-based; HB: hospital-based.